Nowadays, as the age of women giving birth constantly increases, artificial human reproduction (ART) is facing new challenges.
In recent years, assisted reproduction specialists administer PRP (Platelet-Rich Plasma) – still in an experimental stage – to IVF patients in order to treat infertility.
PRP (Platelet-Rich Plasma) is an autologous concentration of human platelets in a small volume of plasma that is produced by blood centrifugation.
For a healthy human organization, the number of platelets ranges between 150.000 and 350.000 / l. However, in order to be considered PRP, the concentration should be 3 to 5 times higher than the regular one in blood plasma.
PRP’s contribution to the natural healing process of the human body has led to its expansive adoption by the medical community in recent years, especially in orthopaedics, dermatology and gynaecology – particularly in assisted reproduction.
In gynaecology, the use of PRP seems to be gaining ground as women, especially those in the western world, try to achieve pregnancy in an older age. As a result of this, the reaction of the ovary does not allow for production of sufficient amount of quality eggs.
Platelet Rich Plasma
The rejuvenating nature of PRP is thought to produce more and better quality eggs, as stem cells are present in the ovary. PRP also helps to increase the thickness of endometrium – a key factor in achieving pregnancy through assisted reproduction -, which on the day of embryo transfer must be at least 7mm.
Since no specific protocol for the treatment of the thin endometrium has been established to
date, the desired thickness is attempted by extended dosage of estrogens and low doses of aspirin.
PRP dosage is recommended in cases of early ovarian failure, poor reaction to at least
one ovarian stimulation program as well as in cases of at least one cancelled IVF cycle due
to inadequate thickness of the endometrium.